-
ACLA Urges FDA To Adopt Greater Flexibility Predetermined Change Control Plans (PCCPs)
-
ACLA Applauds Congressional Action to Delay Medicare Cuts, Urges Long-Term Reform
Washington, D.C.— The American Clinical Laboratory Association (ACLA) today commended Congress for including much-needed relief from looming Medicare payment cuts to clinical laboratory services in ... Read More -
ACLA Comments on CY 2025 PFS Proposed Rule
-
ACLA Response to Cures 2.0 RFI
-
ACLA Statement to Ways & Means Committee on Innovation Field Hearing
-
ACLA Weighs in on American Privacy Rights Act (APRA)
-
ACLA Challenges FDA’s Final Rule to Regulate Laboratory Developed Testing Services as Medical Devices
Washington, D.C. – Today the American Clinical Laboratory Association (ACLA) and its member company, HealthTrackRx, filed a lawsuit against the U.S. Food and Drug Administration ... Read More -
ACLA Challenge to FDA’s Final Rule Regulating Laboratory Developed Testing Services as Medical Devices
-
ACLA Response to CMS RFI on Medicare Advantage Data
-
ACLA Statement on FDA Final Rule to Regulate Laboratory Developed Testing Services as Medical Devices
Washington, D.C. – In response to the U.S. Food & Drug Administration (FDA) releasing its Final Rule to regulate laboratory developed testing services as medical ... Read More